At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
RAD001 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of RAD001 Plus Carboplatin in Patients With Triple-Negative Metastatic Breast Cancer
In Brief
A Phase 2 clinical trial evaluating RAD001 and Carboplatin for Breast Cancer. Completed, enrolled 25 participants across 1 site.
Detailed Summary
This study investigates the effectiveness of combination of carboplatin and investigational agent RAD001 in triple-negative breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsNovartis Pharmaceuticals
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2010
Enrollment StartJun 2010
Primary CompletionNov 2012
Study CompletionMar 2013
TodayJul 2026
First PostedMay 21, 2010
Enrollment StartJun 1, 2010
Primary CompletionNov 1, 2012
Study CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 16.1 years ago
Interventions
RAD001drug
Carboplatindrug